PYC Therapeutics Limited Share Price
Stocks
PYC
AU000000PYC7
Biotechnology & Medical Research
OTC Markets Traded|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.670 AUD | 0.00% |
|
+7.72% | +1.21% |
| 07-15 | PYC Therapeutics Limited - Shareholder/Analyst Call | |
| 07-08 | PYC Therapeutics Says US Patent Office Grants Composition of Matter Patents for Three Drug Candidates | MT |
| Market Cap | 1.64B 1.15B 1.01B 930M 853M 1.61B 111B 11.09B 4.35B 54.11B 4.32B 4.22B 187B | P/E 2026 * |
-23.4x | P/E 2027 * | -17.2x |
|---|---|---|---|---|---|
| Enterprise Value | 975M 683M 597M 552M 506M 958M 65.78B 6.58B 2.59B 32.12B 2.56B 2.51B 111B | EV / Sales 2026 * |
266x | EV / Sales 2027 * | - |
| Free-Float |
70.64% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: PYC Therapeutics Limited
| 03-16 | Bell Potter rates PYC as Speculative Buy | AQ |
| 09/09/25 | Bell Potter rates PYC as Speculative Buy | AQ |
| 07/11/24 | PYC Therapeutics : Anti Bribery & Anti Corruption Policy | PU |
| 07/11/24 | PYC Therapeutics : Definition of Independence | PU |
| 07/11/24 | PYC Therapeutics : Continuous Disclosure Policy | PU |
| 1 day | +0.30% | ||
| 1 week | +7.72% | ||
| Current month | -0.59% | ||
| 1 month | +25.47% | ||
| 3 months | +30.86% | ||
| 6 months | -0.89% | ||
| Current year | +1.21% |
| 1 week | 1.52 |  | 1.68 |
| 1 month | 1.34 | | 1.76 |
| Current year | 1.04 | | 1.76 |
| 1 year | 0.85 | | 1.76 |
| 3 years | 0.52 | | 2.1 |
| 5 years | 0.5 | | 2.1 |
| 10 years | 0.12 | | 2.1 |
| Manager | Title | Age | Since |
|---|---|---|---|
Rohan Hockings
CEO | Chief Executive Officer | 42 | 18/08/2020 |
Thomas Ulmer
DFI | Director of Finance/CFO | 47 | 06/07/2026 |
Sri Mudumba
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Rohan Hockings
BRD | Director/Board Member | 42 | 29/11/2018 |
Ian Constable
BRD | Director/Board Member | - | 21/09/2025 |
Peter Coleman
CHM | Chairman | 66 | 17/11/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 27/03/26 | Buy | Chief Executive Officer | 82,550 | 0.0085% | ||
| 10/03/26 | Buy | Chief Executive Officer | 80,010 | 0.0082% | ||
| 23/12/25 | Free | Chairman | 2,000,000 | 0.3429% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | +7.72% | +23.62% | +153.79% | 1.11B | |
| -1.07% | -1.27% | +0.95% | +5.66% | 50.35B | |
| -2.85% | -6.25% | +366.61% | +572.09% | 39.21B | |
| +1.78% | +0.73% | +32.68% | -4.80% | 34.52B | |
| +1.98% | +4.82% | +13.71% | +61.68% | 34.6B | |
| +0.06% | +1.56% | +4.41% | +27.42% | 27.05B | |
| -3.27% | -5.67% | - | - | 16.68B | |
| +1.64% | +0.45% | +70.86% | +121.18% | 15.11B | |
| +0.29% | +1.02% | +14.95% | +17.80% | 13.85B | |
| -1.21% | +0.73% | +18.02% | -30.96% | 13.18B | |
| Average | -0.24% | +0.46% | +60.65% | +102.65% | 24.57B | |
| Weighted average by Cap. | -0.31% | +0.43% | +77.24% | +119.08% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.67M 2.57M 2.24M 2.08M 1.9M 3.6M 247M 24.75M 9.72M 121M 9.64M 9.43M 417M | - |
| Net income | -61.32M -42.93M -37.52M -34.7M -31.84M -60.27M -4.14B -414M -163M -2.02B -161M -158M -6.97B | -91.46M -64.04M -55.97M -51.76M -47.5M -89.9M -6.17B -617M -243M -3.01B -240M -235M -10.4B |
| Net Debt | -667M -467M -408M -378M -347M -656M -45.03B -4.5B -1.77B -21.99B -1.75B -1.72B -75.91B | -584M -409M -358M -331M -304M -574M -39.43B -3.94B -1.55B -19.25B -1.54B -1.5B -66.47B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/07/26 | A$1.670 | 0.00% | 83,417 |
| 16/07/26 | A$1.670 | +3.41% | 1,009,061 |
| 15/07/26 | A$1.615 | +6.60% | 1,205,445 |
| 14/07/26 | A$1.515 | -2.26% | 692,339 |
| 13/07/26 | A$1.550 | -0.32% | 433,292 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PYC Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
